These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32976881)

  • 1. Expression and clinical significance of CXC chemokines in the glioblastoma microenvironment.
    Li C; Deng H; Zhou Y; Ye Y; Zhao S; Liang S; Cai S; Lin J; Tang Y; Wu Y
    Life Sci; 2020 Nov; 261():118486. PubMed ID: 32976881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of prognostic value and immune infiltration of CXC chemokines in pancreatic cancer.
    Jing Y; Wang F; Zhang K; Chen Z
    BMC Med Genomics; 2022 Apr; 15(1):96. PubMed ID: 35468838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of prognostic biomarkers and therapeutic targets in the microenvironment of bladder cancer based on CXC chemokines.
    Sun X; Chen Q; Zhang L; Chen J; Zhang X
    Math Biosci Eng; 2021 Jul; 18(5):6262-6287. PubMed ID: 34517533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in hepatocellular carcinoma microenvironment.
    Yin Z; Ma T; Chen S; Yu M
    Cancer Biomark; 2023; 36(3):231-250. PubMed ID: 36938723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Analysis of CD163 as a Prognostic Biomarker and Associated with Immune Infiltration in Glioblastoma Multiforme.
    Li H; Wang D; Yi B; Cai H; Xi Z; Lou X; Li Z
    Biomed Res Int; 2021; 2021():8357585. PubMed ID: 34395626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Expression of the Chemokine CXCL14 Correlates with Several Aggressive Aspects of Glioblastoma and Promotes Key Properties of Glioblastoma Cells.
    Fazi B; Proserpio C; Galardi S; Annesi F; Cola M; Mangiola A; Michienzi A; Ciafrè SA
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31117166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in the Renal Cell Carcinoma Microenvironment.
    Zeng Q; Sun S; Li Y; Li X; Li Z; Liang H
    Front Oncol; 2019; 9():1555. PubMed ID: 32117786
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of Potential Therapeutic Targets Among CXC Chemokines in Breast Tumor Microenvironment Using Integrative Bioinformatics Analysis.
    Chen E; Qin X; Peng K; Xu X; Li W; Cheng X; Tang C; Cui Y; Wang Z; Liu T
    Cell Physiol Biochem; 2018; 45(5):1731-1746. PubMed ID: 29495008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of therapeutic targets and prognostic biomarkers of CXC chemokines in cervical cancer microenvironment.
    Kong W; Zhao G; Chen H; Wang W; Shang X; Sun Q; Guo F; Ma X
    Cancer Cell Int; 2021 Jul; 21(1):399. PubMed ID: 34321012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of Tim-3 expression with chemokine levels for predicting the prognosis of patients with glioblastoma.
    Zhu Z; Zhang X; Yu Z; Zhou Y; Zhu S; Zhang YH; Lin XP; Mou Y; Zhang J
    J Neuroimmunol; 2021 Jun; 355():577575. PubMed ID: 33901809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in Pancreatic Ductal Adenocarcinoma Microenvironment.
    Yin Z; Chen S
    Pancreas; 2022 Oct; 51(9):1235-1247. PubMed ID: 37078951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Significance and Therapeutic Target of CXC Chemokines in the Microenvironment of Lung Adenocarcinoma.
    Wang K; Li R; Zhang Y; Qi W; Fang T; Yue W; Tian H
    Int J Gen Med; 2022; 15():2283-2300. PubMed ID: 35250303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of potential therapeutic and prognostic value of CXC chemokines in cervical squamous cell carcinoma and endocervical adenocarcinoma based on bioinformatics analysis.
    Wu C; Ma C; Yuan J; Zhou P
    Math Biosci Eng; 2021 Sep; 18(6):8201-8222. PubMed ID: 34814296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment.
    Chang N; Ahn SH; Kong DS; Lee HW; Nam DH
    Mol Cell Endocrinol; 2017 Aug; 451():53-65. PubMed ID: 28089821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Microenvironment Characterization in Glioblastoma Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures.
    Zhang J; Xiao X; Zhang X; Hua W
    J Mol Neurosci; 2020 May; 70(5):738-750. PubMed ID: 32006162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioinformatics analysis of the role of CXC ligands in the microenvironment of head and neck tumor.
    Jing F; Wang J; Zhou L; Ning Y; Xu S; Zhu Y
    Aging (Albany NY); 2021 Jul; 13(13):17789-17817. PubMed ID: 34247149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma.
    Huang J; Chen Z; Ding C; Lin S; Wan D; Ren K
    Front Oncol; 2021; 11():711402. PubMed ID: 34497764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of the prognosis and immune infiltration for CXC chemokines in colorectal cancer.
    Yang X; Wei Y; Sheng F; Xu Y; Liu J; Gao L; Yang J; Sun X; Huang J; Guo Q
    Aging (Albany NY); 2021 Jul; 13(13):17548-17567. PubMed ID: 34233297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management.
    Ullah A; Jiao W; Shen B
    Cell Mol Biol Lett; 2024 May; 29(1):73. PubMed ID: 38745115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BACH1 as a potential target for immunotherapy in glioblastomas.
    Yuan F; Cong Z; Cai X; Zhu J; Yuan L; Wang Y; Tang C; Ma C
    Int Immunopharmacol; 2022 Feb; 103():108451. PubMed ID: 34923423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.